Sell Trimeris Down to 50 Cents
Trimeris, Inc. (TRMS - Analyst Report) develops therapeutic agents for the treatment of viral diseases based on its fusion inhibition technology that blocks viral entry into host cells. Sales of its lead drug Fuzeon has been declining dramatically since 1Q08 due to fierce competition from Selzentry and Isentress.
The collaboration amendment with Roche and several management changes further cast a shadow on the company's future. We maintain our Sell rating on Trimeris with a $0.50 price target.
At this point, it's very difficult to value the stock. We believe qualitative factors prevail currently. There are many uncertainties about Trimeris due to the management change and collaboration amendment with Roche. The company is profitable but will find it tough to stay so if Fuzeon sales continue their downward slide.
Read the full analyst report on TRMS
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 08, 2009 03:37 am ET |
Sponsored Links

Sponsored Links 
-0.56 %

17.46
[CLICK TO CLOSE X]